Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FILANA THERAPEUTICS, INC.SAVA · Entity 7294 | Chief Business Officer | April 17, 2025 | April 21, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FILANA THERAPEUTICS, INC.
Report date April 17, 2025 · Filed April 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.44 · Expires 2035-04-17 | Direct | 100,000 |
Reported balance
After 2025-04-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-17 · Grant · Acquired 100,000 · Balance 100,000 F1: The stock option vests in four equal annual installments (25% each year) with the initial 25% vesting on April 17, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in four equal annual installments (25% each year) with the initial 25% vesting on April 17, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 17, 2025 Filed Apr 21, 2025 20:45 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001437749-25-012549 · rdgdoc.xml · derivative · entry 1 Nassif Freda · CIK 0002045036 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-04-17 F1 · derivative.exercise_date: The stock option vests in four equal annual installments (25% each year) with the initial 25% vesting on April 17, 2026. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 21:35 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $27.95 | $0.00 |
DisclosureSEC source: 0001437749-24-035868 · rdgdoc.xml · derivative · entry 1 Nassif Freda · CIK 0002045036 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-11-18 F1 · derivative.exercise_date: The stock option vests in four equal annual installments (25% each year) with the initial 25% vesting on November 18, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.